Skip to content

Randomized double-blind controlled trial for Qinxiang Qingjie oral liquid in the treatment of influenza (interior and exterior heat syndrome) in child

Randomized double-blind controlled trial for Qinxiang Qingjie oral liquid in the treatment of influenza (interior and exterior heat syndrome) in child

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021060
Enrollment
Unknown
Registered
2019-01-27
Start date
2019-02-18
Completion date
Unknown
Last updated
2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group:Qinxiang Qingjie oral liquid

Sponsors

First Teaching Hospital of Tianjin University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Child who is diagnosed as influnza with the TCM syndrome of interior and exterior heat; 2. Aged 1 to 13 years old; 3. Course of fever = 38 degrees C; 4. The informed consent process complies with the requirement, and the legal representative or the child (>= 8 years old) sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. With the diagnose of pharyngo-conjuctival fever, herpangina, suppurative tonsillitis, etc; 2. With complicating of sinusitis, otitis media, bronchitis, pneumonia, etc; 3. Severe or critical cases of influenza; 4. Antiviral drugs have been used within 48 hours; 5. Influnza vaccination has been accepted within 12 months; 6. Receiving steroid therapy or other immunosuppressive therapy systematically; 7. With the history of epilepsy or febrile convulsion, recurrent respiratory tract infection; 8. Patients with Severe malnutrition, rickets or cardiovascular, liver, kidney, brain, and hematopoietic system disease; 9. Allergic to the experimental drugs or allergic constitution (allergic to two or more kinds of food or drug); 10. According to the judgment of the investigators, there are other diseases or conditions that reduce the possibility of enrollment or complicate enrollment.

Design outcomes

Primary

MeasureTime frame
Clinical recovery time (day);

Secondary

MeasureTime frame
Time of Completely antifebrile (h);occurrence rate of complication/severy cases;virus negative rate;Curative effect of TCM syndrome;occurrence rate of AE;laboratory examination;vital signs;

Countries

China

Contacts

Public ContactJiaxuan YU

Guangzhou Yipinhong Parmacy co. LTD

mani-yu@163.com+86 020-28877666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026